Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According to GlobalData, Phase II drugs for Cutaneous Squamous Cell Carcinoma (cSCC) have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Fosifloxuridine nafalbenamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Fosifloxuridine nafalbenamide overview

Fosifloxuridine nafalbenamide (NUC-3373) is under development for the treatment of advanced solid tumors including colorectal cancer, cholangiocarcinoma, pleural mesothelioma, basal cell carcinoma, hodgkin lymphoma (b-cell hodgkin lymphoma), metastatic renal cell carcinoma, metastatic transitional cell carcinoma (urothelial cell carcinoma), head and neck squamous cell carcinoma, esophageal cancer, metastatic colorectal cancer, gastric cancer, triple-negative breast cancer, endometrial cancer, metastatic melanoma, non-small cell lung cancer. The drug candidate consists of the active anti-cancer metabolite, FUDR-MP and a protective phosphoramidate moiety. It is a small molecule administered intravenously. The drug candidate is developed based on Protide technology platform.
It was also under development for the treatment of advanced breast cancer.

NuCana overview

NuCana is a clinical-stage biopharmaceutical company that develops novel and transformational medicines for the treatment of cancer. The company pipeline products include NUTIDE-302, NUTIDE-323, NUTIDE-303 and NUTIDE-701 under the clinical studies NUC-3373 and NUC-7738. The company’s product candidates treat colorectal cancer, solid tumor and lung cancer, among others. NuCana develops products based on the ProTide technology platform, which focuses on developing new-generation, anti-cancer agents. The company operates in UK and the US. NuCana is headquartered in Edinburgh, Scotland, the UK

For a complete picture of Fosifloxuridine nafalbenamide’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.